
News|Podcasts|July 30, 2025
Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC
Kevin Chen, PharmD, MS, BCOP, CPP; and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the newly approved drug taletrectinib.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
FDA Approves Lerodalcibep for Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
5

















































































































































































































